Systemic treatment options for brain metastases from non–small-cell lung cancer

Ajaz Bulbul, Patrick M. Forde, Ayesha Murtuza, Brian Woodward, Hannah Yang, Ingmar Bastian, Parissa K. Ferguson, Fernando Lopez-Diaz, David S. Ettinger, Hatim Husain

Research output: Contribution to journalArticlepeer-review

Abstract

Brain metastases are common in patients with non–small-cell lung cancer (NSCLC). Because of associated poor prognosis and limited specific treatment options, there is a real need for the development of medical therapies and strategies for affected patients. Novel compounds for epidermal growth factor receptor–dependent and anaplastic lymphoma kinase–dependent lung cancer have demonstrated blood-brain barrier permeability and have led to important improvements in central nervous system outcomes. Studies of targeted therapies for oncogene-driven tumors and of immunotherapies in patients with brain metastases have shown promise and, allied with novel radiation techniques, are driving a rapid evolution in treatment and prognosis for NSCLC brain metastases.

Original languageEnglish (US)
Pages (from-to)156-163
Number of pages8
JournalONCOLOGY (United States)
Volume32
Issue number4
StatePublished - 2018

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Systemic treatment options for brain metastases from non–small-cell lung cancer'. Together they form a unique fingerprint.

Cite this